This is Why Investors Are Excited About the Potential of Rare Cannabinoids April 21, 2022 - Baystreet.ca Cannabinoids, such as cannabidivarin (CBDV) may be rare, but may also have exciting potential. In fact, according to InMed Pharmaceuticals Inc. (NASDAQ: INM), “CBDV is one of the most studied rare cannabinoids and has been the subject of research in autism, epilepsy, acne, alopecia, inflammatory bowel disease, nausea, and pain. CBDV is also currently being studied in a number of clinical trials including autism, Prader-Willi Syndrome, and attention deficit hyperactivity disorder (ADHD).” In addition, as noted by Rare Cannabinoid Company, “CBDV is a varin. Varins contain two fewer carbon atoms than their non-varin counterparts (THC and CBD). These differences mean that they interact with the human endocannabinoid system in different ways and have unique physiological effects.” In short, the future may be bright for companies, like InMed Pharmaceuticals, which just announced it has launched B2B sales of the rare cannabinoid cannabidivarin to wholesalers, suppliers and end-product manufacturers in the health and wellness sector through its US subsidiary, BayMedica LLC. Other related companies to be aware of include Tilray Inc. (NASDAQ: TLRY), Canopy Growth (TSX: WEED) (NASDAQ: CGC), Jazz Pharmaceuticals (NASDAQ: JAZZ), and AbbVie Inc. (NYSE: ABBV). InMed Pharmaceuticals Inc. (NASDAQ: INM) Just Launched B2B Sales of Cannabidivarin InMed Pharmaceuticals Inc., a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce it has launched B2B sales of the rare cannabinoid cannabidivarin to wholesalers, suppliers and end-product manufacturers in the health and wellness sector through its US subsidiary, BayMedica LLC. “Ensuring a reliable, large volume source of highly pure, bioidentical CBDV is an important step forward in the health and wellness sector. CBDV has been researched for its therapeutic potential in several disease areas such as autism spectrum disorder,” said Shane Johnson, MD, SVP and General Manager of BayMedica. “Whether you are a researcher or product developer at a multinational consumer package goods company, the ability to access highly pure and consistent active ingredients, free from contaminants typically found in plant-sourced cannabinoids such as pesticides, heavy metals, or potentially even THC, is a fundamental requirement. BayMedica’s cannabinoid manufacturing technologies provides exactly that value and we are excited to continue to introduce to the market additional rare cannabinoids that have previously not been abundantly accessible, including adding THCV to our portfolio in the immediate future.” CBDV – An important twist on CBD CBDV is a non-intoxicating rare cannabinoid that has a similar molecular structure to CBD but with two fewer carbon atoms on its sidechain, resulting in important differences in activity. The BayMedica team has curated a collection of scientific research studies on the physiological and potential therapeutic properties of CBDV. CBDV is one of the most studied rare cannabinoids and has been the subject of research in autism, epilepsy, acne, alopecia, inflammatory bowel disease, nausea, and pain. CBDV is also currently being studied in a number of clinical trials including autism, Prader-Willi Syndrome, and attention deficit hyperactivity disorder (ADHD). Click here to download the white paper. BayMedica – We do cannabinoids differently BayMedica manufactures rare cannabinoids through novel synthetic methods that ensure reproducible quality and purity. The Company’s products are manufactured under food-grade GMP (Good Manufacturing Practice) standards for the health and wellness sector, and are bioidentical to plant-derived compounds. These cannabinoids can be custom formulated for a variety of consumer health and wellness applications including supplements, nutraceuticals, cosmetics and animal health. Utilizing reproducible processes guarantee the purity and consistency of our cannabinoids each and every time. Furthermore, these production methods can be scaled up to meet demand to ensure that clients have an ongoing source of cannabinoids without supply chain concerns. Increasing demand for rare cannabinoids As research continues to identify the unique characteristics of cannabinoids beyond THC and CBD, the use and acceptance of all cannaboinds is poised to grow significantly over the coming months and years. Key indicators that point to significant growth include online analytics, emerging trends in the regulated hemp and marijuana sectors, and R&D among multinational CPGs. Reports such as the December 2021 Grand View Research report, that predicts the retail market for rare cannabinoids will reach US$26 Billion by 2028, adds to the growing body of data. By establishing a reliable supply of these rare cannabinoids at commercial scale, innovative product manufacturers and consumer brands now have the ability to deliver improved and differentiated products via product line extensions and formulations designed to increase the performance of their products. For more information on how to purchase CBDV and other rare cannabinoids, please reach out to the BayMedica sales team at: [email protected] Learn more about BayMedica’s products: Minor Cannabinoids CBC CBDV THCV CBT | BayMedica Other related developments from around the markets include: Tilray Inc. reported financial results for the third fiscal quarter. Irwin D. Simon, Tilray’s Chairman and Chief Executive Officer, stated, “Our third quarter results reflect progress and momentum across all of our key business segments and geographies, setting the stage to achieve our target for $4B in revenue by the end of fiscal 2024. Tilray Medical – which now operates under a cohesive strategy and mission – has a near 20% share in Germany, providing clear benefits in its own right as well as a first-mover advantage that we will leverage as Germany and the EU move towards broader adult-use and medical use legalization. In Canada, we maintained our leading market share position amid intense competition – and believe that our strong capital position, operational excellence and pricing and marketing adjustments will work in concert to help ensure we reclaim share in the coming quarters.” Canopy Growth, a world-leading diversified cannabis, hemp, and cannabis device company, is unveiling its 7ACRES Know the Grow content series, providing Canadians with an inside look at the talent, genetics and grow techniques behind the brand and flower portfolio. The ten-video series is broken into three chapters: the 7ACRES Kincardine Facility, Growing Techniques, and 7ACRES Craft Collective + Future Vision, with each episode diving into a different element of production. The series launched in mid-February and releases a new episode weekly via the 7ACRES.com blog, The Stash, as well as on the 7ACRES Instagram channel, @7acresmj. Jazz Pharmaceuticals announced that it will report its 2022 first quarter financial results on Wednesday, May 4, 2022, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2022 first quarter financial results and provide a business and financial update. AbbVie Inc. will announce its first-quarter 2022 financial results on Friday, April 29, 2022, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day. Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. InMed Pharmaceuticals Inc. has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of InMed Pharmaceuticals Inc. Click here for disclaimer. Contact Information: 2818047972 [email protected]
This is Why Investors Are Excited About the Potential of Rare Cannabinoids April 21, 2022 - Baystreet.ca Cannabinoids, such as cannabidivarin (CBDV) may be rare, but may also have exciting potential. In fact, according to InMed Pharmaceuticals Inc. (NASDAQ: INM), “CBDV is one of the most studied rare cannabinoids and has been the subject of research in autism, epilepsy, acne, alopecia, inflammatory bowel disease, nausea, and pain. CBDV is also currently being studied in a number of clinical trials including autism, Prader-Willi Syndrome, and attention deficit hyperactivity disorder (ADHD).” In addition, as noted by Rare Cannabinoid Company, “CBDV is a varin. Varins contain two fewer carbon atoms than their non-varin counterparts (THC and CBD). These differences mean that they interact with the human endocannabinoid system in different ways and have unique physiological effects.” In short, the future may be bright for companies, like InMed Pharmaceuticals, which just announced it has launched B2B sales of the rare cannabinoid cannabidivarin to wholesalers, suppliers and end-product manufacturers in the health and wellness sector through its US subsidiary, BayMedica LLC. Other related companies to be aware of include Tilray Inc. (NASDAQ: TLRY), Canopy Growth (TSX: WEED) (NASDAQ: CGC), Jazz Pharmaceuticals (NASDAQ: JAZZ), and AbbVie Inc. (NYSE: ABBV). InMed Pharmaceuticals Inc. (NASDAQ: INM) Just Launched B2B Sales of Cannabidivarin InMed Pharmaceuticals Inc., a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce it has launched B2B sales of the rare cannabinoid cannabidivarin to wholesalers, suppliers and end-product manufacturers in the health and wellness sector through its US subsidiary, BayMedica LLC. “Ensuring a reliable, large volume source of highly pure, bioidentical CBDV is an important step forward in the health and wellness sector. CBDV has been researched for its therapeutic potential in several disease areas such as autism spectrum disorder,” said Shane Johnson, MD, SVP and General Manager of BayMedica. “Whether you are a researcher or product developer at a multinational consumer package goods company, the ability to access highly pure and consistent active ingredients, free from contaminants typically found in plant-sourced cannabinoids such as pesticides, heavy metals, or potentially even THC, is a fundamental requirement. BayMedica’s cannabinoid manufacturing technologies provides exactly that value and we are excited to continue to introduce to the market additional rare cannabinoids that have previously not been abundantly accessible, including adding THCV to our portfolio in the immediate future.” CBDV – An important twist on CBD CBDV is a non-intoxicating rare cannabinoid that has a similar molecular structure to CBD but with two fewer carbon atoms on its sidechain, resulting in important differences in activity. The BayMedica team has curated a collection of scientific research studies on the physiological and potential therapeutic properties of CBDV. CBDV is one of the most studied rare cannabinoids and has been the subject of research in autism, epilepsy, acne, alopecia, inflammatory bowel disease, nausea, and pain. CBDV is also currently being studied in a number of clinical trials including autism, Prader-Willi Syndrome, and attention deficit hyperactivity disorder (ADHD). Click here to download the white paper. BayMedica – We do cannabinoids differently BayMedica manufactures rare cannabinoids through novel synthetic methods that ensure reproducible quality and purity. The Company’s products are manufactured under food-grade GMP (Good Manufacturing Practice) standards for the health and wellness sector, and are bioidentical to plant-derived compounds. These cannabinoids can be custom formulated for a variety of consumer health and wellness applications including supplements, nutraceuticals, cosmetics and animal health. Utilizing reproducible processes guarantee the purity and consistency of our cannabinoids each and every time. Furthermore, these production methods can be scaled up to meet demand to ensure that clients have an ongoing source of cannabinoids without supply chain concerns. Increasing demand for rare cannabinoids As research continues to identify the unique characteristics of cannabinoids beyond THC and CBD, the use and acceptance of all cannaboinds is poised to grow significantly over the coming months and years. Key indicators that point to significant growth include online analytics, emerging trends in the regulated hemp and marijuana sectors, and R&D among multinational CPGs. Reports such as the December 2021 Grand View Research report, that predicts the retail market for rare cannabinoids will reach US$26 Billion by 2028, adds to the growing body of data. By establishing a reliable supply of these rare cannabinoids at commercial scale, innovative product manufacturers and consumer brands now have the ability to deliver improved and differentiated products via product line extensions and formulations designed to increase the performance of their products. For more information on how to purchase CBDV and other rare cannabinoids, please reach out to the BayMedica sales team at: [email protected] Learn more about BayMedica’s products: Minor Cannabinoids CBC CBDV THCV CBT | BayMedica Other related developments from around the markets include: Tilray Inc. reported financial results for the third fiscal quarter. Irwin D. Simon, Tilray’s Chairman and Chief Executive Officer, stated, “Our third quarter results reflect progress and momentum across all of our key business segments and geographies, setting the stage to achieve our target for $4B in revenue by the end of fiscal 2024. Tilray Medical – which now operates under a cohesive strategy and mission – has a near 20% share in Germany, providing clear benefits in its own right as well as a first-mover advantage that we will leverage as Germany and the EU move towards broader adult-use and medical use legalization. In Canada, we maintained our leading market share position amid intense competition – and believe that our strong capital position, operational excellence and pricing and marketing adjustments will work in concert to help ensure we reclaim share in the coming quarters.” Canopy Growth, a world-leading diversified cannabis, hemp, and cannabis device company, is unveiling its 7ACRES Know the Grow content series, providing Canadians with an inside look at the talent, genetics and grow techniques behind the brand and flower portfolio. The ten-video series is broken into three chapters: the 7ACRES Kincardine Facility, Growing Techniques, and 7ACRES Craft Collective + Future Vision, with each episode diving into a different element of production. The series launched in mid-February and releases a new episode weekly via the 7ACRES.com blog, The Stash, as well as on the 7ACRES Instagram channel, @7acresmj. Jazz Pharmaceuticals announced that it will report its 2022 first quarter financial results on Wednesday, May 4, 2022, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2022 first quarter financial results and provide a business and financial update. AbbVie Inc. will announce its first-quarter 2022 financial results on Friday, April 29, 2022, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day. Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. InMed Pharmaceuticals Inc. has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of InMed Pharmaceuticals Inc. Click here for disclaimer. Contact Information: 2818047972 [email protected]